GlassScriptPhysician profile
Jason Ceavers
NPI 1205497005
$6,312.01
in general payments reported to CMS, 2019-2025
22 companies · $1,271 in 2025
The $1,271 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $295 · 2023: $2,199 · 2024: $2,547 · 2025: $1,271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,767 · Consulting Fee: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,767.04 |
| Consulting Fee | $1,250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $3,335.60 | 2022-2025 | Apretude, Dovato, Cabenuva |
| Gilead Sciences, INC. | $1,342.73 | 2023-2025 | Descovy, Biktarvy |
| Novo Nordisk INC | $619.34 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Argon Medical Devices, INC. | $147.16 | 2025 | Clot Management |
| Edwards Lifesciences Corporation | $137.47 | 2024 | |
| Davol INC. | $90.91 | 2025 | Phasix Mesh |
| Emd Serono, INC. | $84.66 | 2023-2025 | Serostim |
| Abbott Laboratories | $77.46 | 2024-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $74.49 | 2022-2023 | Trelegy Ellipta |
| Lilly USA, LLC | $60.17 | 2023-2024 | Mounjaro, Zepbound |
| Theratechnologies INC. | $59.10 | 2023 | Trogarzo, Egrifta |
| Merck Sharp & Dohme LLC | $57.31 | 2022-2025 | Pifeltro, Delstrigo, Capvaxive |
| Amgen INC. | $46.06 | 2023-2025 | Otezla, Repatha, Otezla |
| Exact Sciences Corporation | $29.73 | 2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $26.25 | 2024 | Watchman Flx |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $24.49 | 2023 | |
| Novartis Pharmaceuticals Corporation | $19.85 | 2024 | |
| Antares Pharma, INC. | $19.78 | 2023 | Nocdurna, Xyosted, Tlando |
| Dexcom, INC. | $15.43 | 2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $15.34 | 2024 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.83 | 2023 | Xifaxan |
| Pfizer INC. | $13.85 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Ceavers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.